{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:26:02Z","timestamp":1781889962441,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ejca.2014.07.017","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T05:45:37Z","timestamp":1411623937000},"page":"2897-2904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct00506805","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct016111623","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jeffrey R.","family":"Infante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Tibes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C.","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James M.","family":"Hinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everardus O.","family":"Orlemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh K.","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2014.07.017_b0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"Neckers","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0010","doi-asserted-by":"crossref","first-page":"23843","DOI":"10.1074\/jbc.272.38.23843","article-title":"The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP\/ADP switch domain that regulates hsp90 conformation","volume":"272","author":"Grenert","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2014.07.017_b0015","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2007.11.7960","article-title":"Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study","volume":"25","author":"Modi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.07.017_b0020","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1158\/1078-0432.CCR-10-0503","article-title":"Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin","volume":"16","author":"Vaishampayan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2011.08664.x","article-title":"Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1\/2 study","volume":"153","author":"Richardson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2014.07.017_b0030","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","article-title":"Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies","volume":"23","author":"Banerji","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.07.017_b0035","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"13","author":"Solit","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0040","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/0008-5472.CAN-08-3131","article-title":"Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells","volume":"69","author":"Gaspar","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1078-0432.CCR-07-1667","article-title":"SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers","volume":"14","author":"Chandarlapaty","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0050","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2008-04-151928","article-title":"SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK","volume":"113","author":"Okawa","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2014.07.017_b0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1593\/tlo.13292","article-title":"Hsp90 inhibitor SNX5422\/2112 targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell carcinoma","volume":"6","author":"Friedman","year":"2013","journal-title":"Transl. Oncol"},{"key":"10.1016\/j.ejca.2014.07.017_b0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2014.07.017_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2014.07.017_b0070","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-06-2233","article-title":"Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers","volume":"13","author":"Ramanathan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-13-152","article-title":"A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies","volume":"13","author":"Goldman","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2014.07.017_b0080","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1158\/1078-0432.CCR-13-0953","article-title":"A phase 1 study of the heat shock protein 90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft tissue sarcomas","volume":"19","author":"Wagner","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0085","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-12-3404","article-title":"First-in-human phase 1 dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors","volume":"19","author":"Sessa","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0090","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2005.12.085","article-title":"Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors","volume":"23","author":"Grem","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.07.017_b0095","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","article-title":"A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas","volume":"17","author":"Rajan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.07.017_b0100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2010.08265.x","article-title":"Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2014.07.017_b0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10637-010-9493-4","article-title":"A Phase II trial of 17-allylamino, 17-demethoxy-geldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma","volume":"30","author":"Pacey","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2014.07.017_b0110","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.3028","article-title":"First in human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors","volume":"30","author":"Mahadevan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.07.017_b0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/annonc\/mds275","article-title":"Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors","volume":"24","author":"Dickson","year":"2013","journal-title":"Ann Oncol"},{"issue":"M111","key":"10.1016\/j.ejca.2014.07.017_b0120","first-page":"016675","article-title":"Systematic identification of the HSP90 regulated proteome","volume":"11","author":"Wu","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ejca.2014.07.017_b0125","doi-asserted-by":"crossref","unstructured":"London CA, Bear MD, Proia DA. The importance of dose schedule with Hsp90 inhibitors: Results from a Phase II study in dogs with mast cell tumors. The American Association for Cancer Research Annual Meeting, Washington, DC, April 6\u201310; 2013. Abstract 3369.","DOI":"10.1158\/1538-7445.AM2013-3369"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914008697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914008697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T22:54:34Z","timestamp":1717368874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914008697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":25,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0959804914008697"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.07.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}